Aerami Therapeutics Presents New Lung Deposition Modeling Data For AER-901 in Pulmonary Hypertension at the American Thoracic Society 2024 International Conference
20. Mai 2024 17:00 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., May 20, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics to Present New Lung Deposition Modeling Data for AER-901, in Development for Pulmonary Hypertension, at the American Thoracic Society 2024 International Conference
08. Mai 2024 08:30 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., May 08, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
05. Oktober 2023 08:00 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Announces Presentation of Phase 1 Clinical Trial Data for Lead Program AER-901 at the 2023 European Respiratory Society (ERS) International Congress
12. September 2023 09:48 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO and Expands Management Team as Lead Asset AER-901 (inhaled imatinib) Advances Toward Phase 2 in Pulmonary Hypertension
01. Juni 2023 08:00 ET
|
Aerami Therapeutics Inc
Joshua Ziel, PhD, appointed as Chief Operating Officer and interim Chief Executive Officer Gary Burgess, MD, appointed as Chief Medical OfficerSarah Fritchley, PhD, appointed as Senior Vice President,...
Aerami Therapeutics Announces Pharmacokinetic Data Demonstrating the Potential of AER-901 (Inhaled Imatinib) to Achieve Therapeutic Levels at Low Inhaled Doses for Treatment of Pulmonary Hypertension
24. Mai 2023 08:58 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics to Present Pharmacokinetic Data Supporting AER-901 (Inhaled Imatinib) for Pulmonary Hypertension at the 2023 American Thoracic Society (ATS) International Conference
11. Mai 2023 08:00 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Mourns the Sudden Loss of Chief Executive Officer Lisa Yañez
05. Mai 2023 07:00 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., May 05, 2023 (GLOBE NEWSWIRE) -- It is with deep sadness that Aerami Therapeutics (“Aerami”) today announces that our dear friend, fierce patient advocate, dedicated mentor, and CEO,...
Aerami Therapeutics to Host Virtual Investor Day with Leading Experts in Pulmonary Hypertension as AER-901 (Inhaled Imatinib) Advances Toward Phase 2
03. April 2023 09:00 ET
|
Aerami Therapeutics Inc
DURHAM, N.C., April 03, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious and rare...
Aerami Therapeutics Announces Expansion of the AER-901 (inhaled imatinib) Development Program in Pulmonary Hypertension Supported by Phase 1 Clinical Trial Data and Continued Progress
23. Februar 2023 09:00 ET
|
Aerami Therapeutics Inc
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial...